
Rapt Therapeutics (NASDAQ:RAPT - Free Report) - Equities researchers at HC Wainwright cut their Q2 2025 earnings per share estimates for shares of Rapt Therapeutics in a report released on Thursday, July 10th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.66) per share for the quarter, down from their prior estimate of ($0.64). HC Wainwright has a "Buy" rating and a $27.00 price objective on the stock. The consensus estimate for Rapt Therapeutics' current full-year earnings is ($2.14) per share. HC Wainwright also issued estimates for Rapt Therapeutics' Q3 2025 earnings at ($1.17) EPS, Q4 2025 earnings at ($0.97) EPS, FY2025 earnings at ($1.26) EPS, FY2026 earnings at ($1.77) EPS, FY2027 earnings at ($1.19) EPS, FY2028 earnings at ($1.03) EPS and FY2029 earnings at ($1.09) EPS.
Several other equities research analysts have also recently issued reports on the company. Wall Street Zen cut Rapt Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, June 21st. UBS Group reduced their target price on Rapt Therapeutics from $16.00 to $8.00 and set a "neutral" rating on the stock in a report on Thursday, May 22nd. Two analysts have rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $19.80.
Get Our Latest Research Report on RAPT
Rapt Therapeutics Stock Down 2.8%
RAPT stock traded down $0.29 during trading on Monday, reaching $10.23. The company's stock had a trading volume of 90,715 shares, compared to its average volume of 167,946. The company has a market capitalization of $169.20 million, a P/E ratio of -0.53 and a beta of -0.09. The company's fifty day moving average is $8.14 and its 200-day moving average is $8.76. Rapt Therapeutics has a 1 year low of $5.67 and a 1 year high of $29.60.
Rapt Therapeutics (NASDAQ:RAPT - Get Free Report) last issued its quarterly earnings results on Thursday, May 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.48) by $1.84.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently modified their holdings of the company. Picton Mahoney Asset Management lifted its holdings in shares of Rapt Therapeutics by 994.4% in the 4th quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company's stock valued at $26,000 after acquiring an additional 14,697 shares during the last quarter. Simplicity Wealth LLC bought a new position in shares of Rapt Therapeutics in the 1st quarter valued at about $25,000. Exchange Traded Concepts LLC lifted its holdings in shares of Rapt Therapeutics by 27.7% in the 1st quarter. Exchange Traded Concepts LLC now owns 113,738 shares of the company's stock valued at $139,000 after acquiring an additional 24,662 shares during the last quarter. Callan Family Office LLC lifted its holdings in shares of Rapt Therapeutics by 53.9% in the 1st quarter. Callan Family Office LLC now owns 89,327 shares of the company's stock valued at $109,000 after acquiring an additional 31,287 shares during the last quarter. Finally, Comerica Bank lifted its holdings in shares of Rapt Therapeutics by 53.9% in the 1st quarter. Comerica Bank now owns 89,327 shares of the company's stock valued at $109,000 after acquiring an additional 31,287 shares during the last quarter. 99.09% of the stock is currently owned by institutional investors.
About Rapt Therapeutics
(
Get Free Report)
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.
Further Reading

Before you consider Rapt Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rapt Therapeutics wasn't on the list.
While Rapt Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.